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Background: Oesophageal adenocarcinoma (OAC) is a highly aggressive malignancy with poor survival,
which is highly variable amongst patients with comparable conventional prognosticators. Therefore
molecular biomarkers are urgently needed to improve the prediction of survival in these patients. SRY
(sex determining region Y)-box 2, also known as SOX2, is a transcription factor involved in embryonal
development of the gastrointestinal tract as well as in carcinogenesis. The purpose of this study was to
see whether SOX2 expression is associated with survival in patients with OAC.
Methods: SOX2 was studied by immunohistochemistry in patients who had undergone potentially
curative oesophagectomy for adenocarcinoma. Protein expression of SOX2 was evaluated using tissue
microarrays from resection specimens, and results were analysed in relation to the clinical data by Cox
regression analysis. SOX2 was evaluated in two independent OAC cohorts (Rotterdam cohort and a
multicentre UK cohort).
Results: Loss of SOX2 expression was independently predictive of adverse overall survival in the
multivariable analysis, adjusted for known factors influencing survival, in both cohorts (Rotterdam cohort:
hazard ratio (HR) 1⋅42, 95 per cent c.i. 1⋅07 to 1⋅89, P=0⋅016; UK cohort: HR 1⋅54, 1⋅08 to 2⋅19,
P= 0⋅017). When combined with clinicopathological staging, loss of SOX2 showed an increased effect
in patients with pT1–2 tumours (P= 0⋅010) and node-negative OAC (P=0⋅038), with an incrementally
adverse effect on overall survival for stage I OAC with SOX2 loss (HR 3⋅18, 1⋅18 to 8⋅56; P=0⋅022).
Conclusion: SOX2 is an independent prognostic factor for long-term survival in OAC, especially in
patients with stage I OAC.
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Introduction
Oesophageal adenocarcinoma (OAC) is an aggressive can-
cer with a steadily increasing incidence1,2. The major risk
factors for OAC are gastro-oesophageal reflux3, abdom-
inal obesity4 and Barrett’s oesophagus5,6. Patients with
non-dysplastic Barrett’s oesophagus have a low rate of pro-
gression to OAC during surveillance (less than 1 per cent
per year)7, but most patients with OAC exhibit underlying
Barrett’s oesophagus at the time of OAC diagnosis and are
typically diagnosed at an advanced stage8.
Although the addition of neoadjuvant therapy to pri-
mary surgical resection improves overall survival (OS) and
disease-specific survival in patients with locally advanced
tumours, the prognosis of most patients with advanced
OAC, including those treated with curative intent, is dis-
mal, with a 5-year survival rate of 47 per cent at best9–11.
Postsurgical prognostication is currently based on tumour
staging according to the AJCC staging system, supple-
mented by pathological criteria12.However, even after con-
sidering all known parameters including resection margin,
nodal status, presence of vascular invasion, tumour grade
and differentiation grade, the course of the disease remains
variable13–15. Improving clinical decision-making is essen-
tial, especially in early OAC. In these patients numerous
treatment modalities are available, depending on tumour
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characteristics, and the best treatment modality for the
individual patient is still amatter of debate.Onemethod for
a better prognostication in earlyOAC is the use of biomark-
ers that might improve decision-making to determine the
optimal treatment strategy.
Various signalling pathways essential for embryonal
development are involved in cancer initiation and
progression, including the sex determining region Y
(SRY)-box2, also known as SOX2. SOX2 is a highly con-
served gene coded on a single exon that plays a pivotal
role in the maintenance of embryonic stem cells16. In
the gastrointestinal tract it determines the formation
and differentiation of oesophageal and gastric epithelium
during embryogenesis17,18. Besides its role in embryoge-
nesis, SOX2 is involved in various malignancies including
squamous cell carcinoma of the oesophagus19, gastric
adenocarcinoma20, prostate21 and colorectal22 cancer.
SOX2 functions differ depending on the cell of origin,
and both oncogenic and tumour suppressive mechanisms
have been described. The SOX2 gene may be amplified in
squamous cell carcinoma of the oesophagus and trachea,
and acts as a lineage survival oncogene by promoting cell
migration and proliferation23,24. Accordingly, upregulation
of SOX2 is strongly associated with adverse outcomes
in these patients19. In contrast, the opposite functions of
SOX2 were shown in gastric adenocarcinoma, in which
loss of SOX2 expression was correlated with worse prog-
nosis. Phosphatase and tensin homologue (PTEN) has
been proposed as a direct target of SOX220.
Little is known about the role of SOX2 in established
OAC, although it has been shown in association with Bar-
rett’s oesophagus25. Non-dysplastic Barrett’s oesophagus
exhibits mixed differentiation and expresses gastric genes
including SOX2 and gastric mucins MUC5A and MUC6,
as well as CDX2 as a marker of intestinal differentiation25.
SOX2 was found in 98 per cent of the biopsies with
non-dysplastic Barrett’s oesophagus, whereas only 72 per
cent of low-grade dysplasia and 29 per cent ofOAC samples
demonstrated SOX2 expression26. Similar observations
were detected for markers of intestinal differentiation27,28.
It was concluded that SOX2, in parallel with the gastric
mucins and intestinal genes, is gradually lost during pro-
gression of Barrett’s oesophagus to OAC26. SOX2 status
has also been shown to be indicative of the pattern of
response to neoadjuvant chemoradiotherapy in patients
with OAC29,30, and one small cohort study31 suggested that
SOX2may have a prognostic effect for disease-free survival
(DFS) in surgically treated patients with OAC.
The aim of the present study was to assess the role
of SOX2 as a prognostic marker in patients with surgi-
cally treated OAC. As SOX2 is lost during progression of
Barrett’s oesophagus to OAC, it was hypothesized that this
gene would have particular influence in stage I OAC.
Methods
Patient selection
To reduce possible bias of neoadjuvant treatment that
might influence SOX2 expression and interfere with
OS, two historical OAC cohorts with a high propor-
tion of patients who had surgical resection alone were
used. Both the Rotterdam cohort and the UK multi-
centre cohort from the OCCAMS (Oesophageal Cancer
Clinical And Molecular Stratification) study included
patients who underwent oesophagectomy with curative
intent for pathologically confirmed adenocarcinoma of the
oesophagus or gastro-oesophageal junction. Follow-up
of all patients was performed in the respective clinical
centres and only patients who were alive 1month after
surgery were included in the analysis. The Rotterdam
cohort consisted of patients treated at the Department of
Surgery at Erasmus Medical Centre, Rotterdam, between
1995 and 2006. The UK cohort comprised patients from
six tertiary hospitals who were treated between 1992
and 2000.
Clinical and pathological data for both cohorts were
collected, including tumour grade, pathological stage,
anatomical location of the tumour divided into three
types as described by Siewert et al.32, chemotherapy, age
at surgery, co-morbidities and OS. The TNM system
according to the UICC seventh edition12 was used for
pathological grading and staging. To ensure reliable
classification, all tumours were reviewed by an expert
gastrointestinal pathologist.
Tissue microarray
For the construction of a tissue microarray (TMA),
formalin-fixed paraffin-embedded tissue from the resec-
tion specimens was retrieved from the archives at the
Departments of Pathology of the participating institu-
tions. For each tumour, three to six cores from multiple
representative areas of OAC, as identified by a pathologist
on haematoxylin and eosin-stained slides, were taken from
the original paraffin blocks, including the central part and
invasive front of the tumour33,34.
SOX2 immunohistochemistry
The SOX2 immunohistochemical staining technique has
been described extensively in previous publications26,29.
In short, 5-μm sections were cut from the TMA,
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Table 1 Clinicopathological characteristics in individual and combined cohorts
Combined cohort (n=756) Rotterdam cohort (n=336) OCCAMS (n=420) P†
Age at surgery (years)* 65⋅4 (33–90) 64⋅7 (33–90) 66⋅0 (33–88) 0⋅009‡
Sex ratio (M : F) 602 : 132 293 : 43 309 : 89 0⋅001
Follow-up (months)* 20⋅9 (1–199) 25⋅0 (1–199) 18⋅0 (1–193) 0⋅004‡
Siewert classification < 0⋅001
Type I 460 (69⋅7) 190 (57⋅1) 270 (82⋅6)
Type II 168 (25⋅5) 126 (37⋅8) 42 (12⋅8)
Type III 32 (4⋅8) 17 (5⋅1) 15 (4⋅6)
Recurrence 182 (54⋅2) 182 (54⋅2) n.a.
Resection margin status 0⋅212
pR0 396 (71⋅0) 245 (72⋅9) 151 (68⋅0)
pR1 162 (29⋅0) 91 (27⋅1) 71 (32⋅0)
Histological grade 0⋅007
Well differentiated 52 (7⋅5) 26 (7⋅7) 26 (7⋅3)
Moderately differentiated 248 (35⋅7) 139 (41⋅4) 109 (30⋅4)
Poorly differentiated 394 (56⋅8) 171 (50⋅9) 223 (62⋅3)
pT category 0⋅001
pT1 79 (11⋅2) 48 (14⋅7) 31 (8⋅2)
pT2 132 (18⋅8) 59 (18⋅0) 73 (19⋅4)
pT3 474 (67⋅3) 218 (66⋅7) 256 (67⋅9)
pT4 19 (2⋅7) 2 (0⋅6) 17 (4⋅5)
pN category <0⋅001
pN0 245 (35⋅9) 142 (42⋅4) 103 (29⋅6)
≥pN1 438 (64⋅1) 193 (57⋅6) 245 (70⋅4)
(Neo)adjuvant treatment < 0⋅001
Yes 214 (31⋅3) 68 (20⋅2) 146 (42⋅1)
No 469 (68⋅7) 268 (79⋅8) 201 (57⋅9)
Alive after 60months 0⋅752
Yes 234 (31⋅0) 106 (31⋅5) 128 (30⋅5)
No 522 (69⋅0) 230 (68⋅5) 292 (69⋅5)
SOX2 < 0⋅001
Negative 436 (66⋅1) 181 (57⋅1) 255 (74⋅3)
Positive 224 (33⋅9) 136 (42⋅9) 88 (25⋅7)
Values in parentheses are percentages unless indicated otherwise; *values are median (range). Data were missing for patients in most categories.
OCCAMS, Oesophageal Cancer Clinical And Molecular Stratification; n.a., not available. †χ2 test, except ‡Student’s t test.
deparaffinized and rehydrated. Tissue from squamous
cell carcinoma with clear positive staining for SOX2 was
placed on each immunohistochemical slide of the TMAs as
a positive control. Antigen retrieval was enhanced by heat-
ing in a Tris buffer. Endogenous peroxidase activity was
blocked by incubating the slides in a solution of 0⋅3 per cent
hydrogen peroxide in phosphate-buffered saline. Primary
SOX2 antibody (AF2018, dilution 1 : 800, goat, polyclonal;
R&D Systems, Abingdon, UK) was applied for 22 h at 4∘C.
The secondary antibody was a biotinylated horse antigoat
IgG antibody (1 : 150, BA-4000; Vector Laboratories,
Peterborough, UK). Visualization was achieved using the
horseradish peroxidase avidin–biotin complex method
and diaminobenzidine. Slides were counterstained with
haematoxylin.
The immunohistochemically stained TMA slides from
both cohorts were digitalized and scored independently by
two investigators blinded to the clinical and pathological
outcome. In case of disagreement, the cores were reviewed
by both investigators simultaneously and consensus was
achieved.
SOX2 was scored as positive or negative in each of the
stained cores. As described previously29, weak or strong
nuclear expression in at least 50 per cent of the tumour
cells was defined as positive, whereas nuclear expression in
less than 50 per cent of tumour cells as well as cytoplas-
mic SOX2 expression were defined as negative. Because
SOX2 expression might be heterogeneous in OAC, the
overall expression in each tumour was calculated from all
corresponding cores. Patients with fewer than three cores
containing cells representative of the original OAC were
excluded from analysis.
The optimal cut-off value of immunohistochemistry with
SOX2 to predict survival was calculated by receiver oper-
ating characteristic (ROC) curve analysis in the Rotter-
dam cohort, using the area under the curve (AUC) as the
performance measure (Fig. S1, supporting information).
Based on this evaluation, absence of SOX2 expression was
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Fig. 1 Kaplan–Meier curves of overall survival of patients with oesophageal adenocarcinoma according to expression of SOX2 in a the
Rotterdam cohort, b the OCCAMS (Oesophageal Cancer Clinical And Molecular Stratification) cohort, and c the combined cohort.
a P= 0⋅002, b P= 0⋅008, c P< 0⋅001 (log rank test)
defined by negative staining of SOX2 in more than 75 per
cent of the cores; otherwise, SOX2 was considered to be
present.
Ethics
The investigational protocols for both cohorts were
approved by the relevant institutional review boards
(MEC-12-469 and LREC 04/Q2006/2).
Statistical analysis
The primary endpoint in this study was 5-year OS, defined
as time from surgery until death. Differences between the
Rotterdam and UK cohorts were analysed using Student’s
t test for normal distributions and the Mann–Whitney
U test for non-normal distributions of continuous vari-
ables, and χ2 test for categorical variables. The equality
of distribution was tested with Levene’s test. Interob-
server variation between the two investigators for scoring
of SOX2 was calculated using Cohen’s κ. Strength of
agreement was categorized as follows: 0⋅00–0⋅20, poor;
0⋅21–0⋅40, fair; 0⋅41–0⋅60, moderate; 0⋅61–0⋅80, good;
and 0⋅81–1⋅00, excellent.
Kaplan–Meier curves were used to plot 5-year survival
by SOX2 status, and the distribution was analysed using the
log rank test. After imputation of missing variables using
a linear regression model, univariable and multivariable
Cox proportional hazard models were applied to estimate
the independent association between SOX2 immuno-
histochemical expression and survival. In the multi-
variable analysis, adjustments were made for the clinical
and pathological factors that were independently predic-
tive in the univariable analysis. In addition, sensitivity
analysis using a multivariable Cox proportional hazards
model excluding all patients receiving chemotherapy
or chemoradiotherapy with adjustment for clinical and
pathological factors was performed to test the role of
SOX2 in these patients. A multivariable analysis adjusted
for all clinicopathological criteria that were independently
predictive in the univariable analysis was performed, to
estimate the independent association between SOX2 and
survival for each of the stage groupings described in the
TNM classification12. pN category was dichotomized
as pN0 and pN+ (pN1–3) groups for the multivariable
analysis. All analyses were performed using SPSS® version
22 software (IBM, Armonk, New York, USA). P< 0⋅050
was considered statistically significant.
Results
Patient characteristics
The OAC cohort from Rotterdam consisted of 336
patients, whereas that from the OCCAMS study com-
prised 420 patients. Clinical characteristics of the patients
from both cohorts are shown in Table 1. Patients from the
OCCAMS cohort were older than those from Rotterdam
(median 66⋅0 versus 64⋅7 years respectively; P= 0⋅009) and
had a shorter median follow-up (18⋅0 versus 25⋅0months;
P= 0⋅004). A greater proportion of patients in the Rotter-
dam cohort had a tumour at the oesophagogastric junction
(Siewert type II) (P< 0⋅001), higher degree of differen-
tiation (P= 0⋅007), earlier pT category (P= 0⋅001) and a
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Table 2 Multivariable analysis of survival for all patients in individual and combined cohorts
Combined cohort (n=402) Rotterdam cohort (n=287) OCCAMS cohort (n=115)
Hazard ratio P Hazard ratio P Hazard ratio P
Age at surgery (per year increase) 1⋅02 (1⋅01, 1⋅03) 0⋅002 n.a. n.a. n.a. n.a.
pT category
pT1 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
pT2 1⋅59 (0⋅93, 2⋅72) 0⋅084 1⋅12 (0⋅55, 2⋅24) 0⋅759 2⋅45 (0⋅99, 6⋅07) 0⋅053
pT3–4 2⋅96 (1⋅80, 4⋅91) <0⋅001 2⋅60 (1⋅40, 4⋅84) 0⋅003 3⋅58 (1⋅46, 8⋅80) 0⋅005
pN category
pN0 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
≥pN1 1⋅68 (1⋅15, 2⋅46) 0⋅011 1⋅57 (1⋅14, 2⋅17) 0⋅006 1⋅89 (0⋅81, 4⋅45) 0⋅121
Resection margin status
pR0 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
pR1 1⋅15 (0⋅88, 1⋅50) 0⋅313 1⋅27 (0⋅93, 1⋅75) 0⋅133 1⋅01 (0⋅66, 1⋅57) 0⋅949
Histological grade
Well/moderately differentiated 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Poorly differentiated 1⋅57 (1⋅25, 1⋅97) <0⋅001 1⋅52 (1⋅13, 2⋅05) 0⋅006 1⋅44 (1⋅04, 2⋅00) 0⋅028
(Neo)adjuvant treatment
Yes 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
No n.a. 1⋅74 (1⋅14, 2⋅67) 0⋅011 n.a.
SOX2
Positive 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Negative 1⋅42 (1⋅14, 1⋅77) 0⋅002 1⋅42 (1⋅07, 1⋅89) 0⋅016 1⋅54 (1⋅08, 2⋅19) 0⋅017
Values in parentheses are 95 per cent confidence intervals. OCCAMS, Oesophageal Cancer Clinical And Molecular Stratification; n.a., not available. For
the corresponding univariable analysis, see Table S2 (supporting information).
Table 3 Multivariable analysis of survival in chemotherapy-naive patients in individual and combined cohorts
Combined cohort (n=297) Rotterdam cohort (n=241) OCCAMS cohort (n= 56)
Hazard ratio P Hazard ratio P Hazard ratio P
Age at surgery (per year increase) 1⋅02 (1⋅01, 1⋅03) 0⋅002 n.a. n.a.
pT category
pT1 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
pT2 1⋅88 (0⋅96, 3⋅68) 0⋅065 1⋅40 (0⋅64, 3⋅09) 0⋅400 3⋅11 (0⋅77, 12⋅52) 0⋅110
pT3–4 3⋅99 (2⋅13, 7⋅48) <0⋅001 3⋅48 (1⋅70, 7⋅09) 0⋅001 4⋅61 (1⋅16, 18⋅33) 0⋅030
pN category
pN0 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
≥pN1 1⋅61 (1⋅15, 2⋅25) 0⋅006 1⋅47 (1⋅04, 2⋅07) 0⋅028 2⋅12 (1⋅04, 4⋅29) 0⋅039
Resection margin status
pR0 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
pR1 1⋅17 (0⋅89, 1⋅54) 0⋅270 1⋅27 (0⋅91, 1⋅76) 0⋅162 1⋅14 (0⋅67, 1⋅94) 0⋅63
Histological grade
Well/moderately differentiated 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Poorly differentiated 1⋅51 (1⋅16, 1⋅97) 0⋅003 1⋅47 (1⋅07, 2⋅03) 0⋅017 n.a.
SOX2
Positive 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Negative 1⋅35 (1⋅04, 1⋅75) 0⋅026 1⋅40 (1⋅03, 1⋅91) 0⋅030 1⋅53 (0⋅95, 2⋅47) 0⋅081
Values in parentheses are 95 per cent confidence intervals. OCCAMS, Oesophageal Cancer Clinical And Molecular Stratification; n.a., not available. For
the corresponding univariable analysis, see Table S4 (supporting information).
greater likelihood of having pN0 disease (P< 0⋅001). Loss
of SOX2 expression was more common in the OCCAMS
cohort (74⋅3 per cent versus 57⋅1 per cent in the Rotterdam
cohort; P< 0⋅001).
In the Rotterdam cohort, 68 patients (20⋅2 per
cent) received neoadjuvant chemoradiotherapy (29) or
chemotherapy (39). In the OCCAMS cohort, 146 patients
(42⋅1 per cent) received neoadjuvant chemotherapy
according to UK guidelines (Table 1).
Association between SOX2 expression and survival
The interobserver agreement for the assessment of SOX2
immunohistochemistry between the two observers was
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1327–1337
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Fig. 2 Kaplan–Meier curves of overall survival in chemotherapy-naive patients with oesophageal adenocarcinoma according to SOX2
expression and clinicopathological staging: a pT category, b pN category and c stage grouping
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excellent (κ = 0⋅92, P< 0⋅001). After exclusion of patients
with fewer than three representative cores available, TMAs
from 537 of 756 patients were used in the final analysis
of SOX2 immunohistochemistry (288 from the Rotterdam
and 249 from the OCCAMS cohort). In total, SOX2 was
positive in 186 cancers and negative in 351. Representative
examples of SOX2 immunohistochemical expression pat-
terns are shown in Fig. S2 (supporting information).
In the Rotterdam cohort, negative SOX2 was associated
with a shorter median OS compared with positive SOX2
(19⋅5 versus 32⋅9months respectively; P= 0⋅001). Median
survival in the OCCAMS cohort was similar to that in the
Rotterdam cohort (15⋅0 and 26⋅0months for negative and
positive SOX2 respectively; P= 0⋅014) (Table S1, support-
ing information). Corresponding Kaplan–Meier curves
for the individual cohorts and the combined group are
depicted in Fig. 1.
SOX2 expression did not correlate with location of the
tumour. In Siewert type I OAC, 32⋅9 per cent of the
tumours showed loss of SOX2, whereas in Siewert type II
and III loss of SOX2 was found in 40⋅3 and 32⋅3 per cent
of tumours respectively (P= 0⋅260).
Univariable analysis showed a hazard ratio (HR) for death
in patients with SOX2 loss of 1⋅54 (95 per cent c.i. 1⋅16
to 2⋅04; P= 0⋅003) for the Rotterdam cohort, 1⋅58 (1⋅12
to 2⋅22; P= 0⋅009) for the OCCAMS cohort and 1⋅55
(1⋅25 to 1⋅93; P< 0⋅001) for the combined cohort (Table S2,
supporting information).
Multivariable regression analysis to test the independent
value of SOX2 in relation to other clinical parameters
showed that SOX2 remained significant for OS in both
individual cohorts as well as in the combined cohort (HR
1⋅42, 95 per cent c.i. 1⋅14 to 1⋅77; P= 0⋅002) (Table 2).
Information on DFS was available only for the Rot-
terdam cohort; SOX2 was independently predictive of
disease recurrence (HR 1⋅37, 95 per cent c.i. 1⋅01 to 1⋅86;
P= 0⋅045) (Table S3 and Fig. S3, supporting information).
In chemotherapy-naive patients, SOX2 loss was con-
firmed as a statistically significant prognostic indicator
of worse OS in both univariable and multivariable anal-
ysis (Table 3; Table S4, supporting information). When
the prognostic value of SOX2 in chemotherapy-naive
patients was examined in relation to clinicopathological
staging, SOX2 showed separation into prognostic groups
for pT1–2 tumours (HR 2⋅36, 95 per cent c.i. 1⋅23 to 4⋅51;
P= 0⋅010), but not for pT3–4 tumours (Fig. 2a; Table S5
and S6, supporting information). Patients with pT1
OAC and loss of SOX2 had a trend towards being pN+
(P= 0⋅070) (Table S7, supporting information,), whereas
for pT2–4 tumours there was no correlation between
SOX2 and nodal status.
When combining SOX2 and pN category, a significant
separation into prognostic groups was detected for patients
with pN0 disease (HR 1⋅71, 95 per cent c.i. 1⋅03 to 2⋅84;
P= 0⋅038), whereas for pN1–3 no effect of SOX2 was seen
(Fig. 2b; Table S8, supporting information).
Based on the findings for pT and pN status,
Kaplan–Meier curves were constructed for the effects
of SOX2 for each TNM stage. Only in stage I disease
was SOX2 loss associated with an increased HR for death
(HR 3⋅18, 95 per cent c.i. 1⋅18 to 8⋅56; P= 0⋅022) (Fig. 2c;
Table S9, supporting information).
During follow-up, 289 chemotherapy-naive patients died
within 5 years of surgery, of whom 194 showed loss of
SOX2. The sensitivity of SOX2 for the prediction of death
within 5 years in these patients was 67⋅1 per cent and the
specificity 51⋅1 per cent. Of the 64 chemotherapy-naive
patients with stage I disease, 19 died within 5 years, of
whom13 showed loss of SOX2.The sensitivity of SOX2 for
prediction of death in chemotherapy-naive patients with
stage I disease was 68 per cent and the specificity 62 per
cent. Positive and negative predictive values and AUC for
all patients, chemotherapy-naive patients and patients with
chemotherapy-naive stage I OAC are shown in Table S10
(supporting information).
Discussion
SOX2 immunohistochemistry adds prognostic information
in patients with OAC. SOX2 loss was predictive of an
adverse outcome in two independent cohorts (Rotterdam
and OCCAMS), with a significant incremental adverse
effect for OS, especially for patients with pN0 and stage
I OAC.
Previous studies that attempted to identify clinically
applicable predictive biomarkers for treatment response
or overall prognosis have often been underpowered35 or
included heterogeneous patient populations with squa-
mous cell carcinoma and adenocarcinoma36. Biomarker
analysis can also be hampered by different neoadju-
vant treatments in advanced OAC, making comparisons
between studies difficult37. Large collaborative projects
using standardized methodology are required to gen-
erate a clinically useful approach. Using this strategy, a
three-gene immunohistochemical panel was shown to be
useful in a previous large multicentre study38. Combin-
ing TNM staging with this immunohistochemical panel
of epidermal growth factor receptor (EGFR), tripartite
motif-containing 44 (TRIM44) and sirtuin 2 (SIRT2)
allowed segregation of patients with stage II and III disease
into distinct prognostic groups, whereas the effect for
stage I was minimal38. This is different from the SOX2
findings reported here.
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Little is yet known about the role of SOX2 in OAC. In
Barrett’s oesophagus, which exhibits mixed intestinal and
gastric differentiation, SOX2 is detected in most patients,
whereas during the progression to OAC downregulation
of gastric and intestinal gene expression, including SOX2,
occurs26–28. In advanced OAC, retained expression of
SOX2 has previously been related to resistance to neoad-
juvant chemoradiotherapy in patients treated according to
the CROSS (ChemoRadiotherapy for Oesophageal cancer
followed by Surgery Study) regimen29,30. An earlier small
Dutch study of 94 patients with surgically treatedOAC also
suggested SOX2 loss to be a predictor of reduced DFS,
although it was underpowered to establish the incremental
value of SOX2 in OS31. The present study focused on sur-
gically treated OAC and not only confirmed the prognos-
tic value of SOX2 for DFS (HR 1⋅37; P= 0⋅045), but also
showed that SOX2 loss predicted adverse OS in patients
with OAC. Importantly, SOX2 status was independent of
all clinical and histological parameters known to influence
survival, including neoadjuvant treatment.
Patients with stage I OAC generally have a good prog-
nosis with 5-year survival rates of 87⋅7 and 73⋅3 per cent
for stages Ia and Ib respectively39. Although patients with
pT1a disease can be treated by endoscopic resection or
surgery alone, treatment of those with pT1b disease is
more controversial owing to the risk of lymph node metas-
tasis. An optimal treatment strategy for these patients is
widely debated40. The benefits of neoadjuvant therapy,
for instance, are unclear41. In the present study, a worse
OS in chemotherapy-naive patients with stage I OAC
was associated with loss of SOX2 (HR 3⋅18; P= 0⋅022).
The results suggest that SOX2 might predict lymph node
metastasis in pT1 OAC, although further studies are
needed to confirm this.
The role of SOX2 in the pathogenesis of OAC is poorly
understood. Significant association of retained SOX2
expression and favourable survival could be explained by
SOX2 function as a tumour suppressor gene, similar to the
findings in gastric carcinoma. Lowermitotic rate, increased
apoptosis, and reduced invasion and dissemination were
detected in patients with gastric cancer with retained
SOX2 expression, compared with findings in those with
SOX2 loss42–44. In line with its tumour suppressive role,
several downstream targets of SOX2 were identified in
gastric cancer, including cyclin D1 (CCND1), phospho-
rylated retinoblastoma 1 (pRB1), cyclin-dependent kinase
inhibitor 1B (CDKN1B), as well as PTEN and phospho-
rylated protein kinase B (pAKT)43–45. Given the lineage-
specific SOX2 function in formation of the stomach and
oesophagus during embryogenesis, the role of SOX2 in
OAC might be similar to that seen in gastric cancer.
The present study has some limitations, including its
retrospective design and the small number of patients with
stage I tumours. The expression of SOX2 was assessed in
TMAs constructed from resection specimens and not in
preoperative biopsies of patients with OAC, which may
also be important. Validation of these results in a prospec-
tive study, and on pretreatment tumour material as well as
resection specimens, still needs to be undertaken. At the
same time, SOX2 detection in this study was performed
by standardized immunohistochemistry, which is readily
reproducible, and although interpretation may be subjec-
tive there was excellent interobserver agreement (κ = 0⋅92),
indicating that accurate classification of SOX2 pattern is
possible.
Immunohistochemical detection of SOX2 provided use-
ful prognostic information in patients with OAC, indepen-
dent of clinical parameters. Use of this marker in addition
to current staging systems could be of particular relevance
in selected populations of patients with node-negative
tumours and those with stage I disease. The precise bio-
logical role of SOX2 in OAC requires further elucidation.
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